FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: A randomized study of the Hellenic Oncology Research Group (HORG)

Breast Cancer Research and Treatment

Volumn 119, Issue 1, 2010, Pages 95-104

  Polyzos, Aristides ^a   Malamos, Nikolaos ^b   Boukovinas, Ioannis ^c   Adamou, Adamos ^d   Ziras, Nikolaos ^e   Kalbakis, Kostas ^f   Kakolyris, Stylianos ^g   Syrigos, Kostas ^h   Papakotoulas, Pavlos ^c   Kouroussis, Charalambos ^f   Karvounis, Nikolaos ^e   Vamvakas, Lambros ^f   Christophyllakis, Charalambos ⁱ   Athanasiadis, Athanasios ^j   Varthalitis, Ioannis ^k   Georgoulias, Vassilis ^f   Mavroudis, Dimitris ^f  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Elena Iliadi Hospital   (Greece)

^c THEAGENIO CANCER HOSPITAL   (Greece)

^d Cyprus Oncology Center   (Cyprus)

^e METAXA CANCER HOSPITAL   (Greece)

^f UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^g UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^h UNIVERSITY OF ATHENS   (Greece)

ⁱ 401 Athens Army Hospital   (Greece)

^j GENERAL HOSPITAL OF LARISSA   (Greece)

^k Agios Georgios General Hospital of Chania   (Greece)

more..

Author keywords

Adjuvant chemotherapy; Breast cancer; Docetaxel; Node positive

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; AXILLARY LYMPH NODE; BONE MARROW TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER RESEARCH; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; FOLLOW UP; HUMAN; HYPERSENSITIVITY REACTION; LUNG EMBOLISM; LYMPH NODE METASTASIS; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 72449138560     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0468-0     Document Type: Article

References (15)

1. EBCTCG 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
2. PM Ravdin HA Burris G Cook, et al. 1995 Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer J Clin Oncol 13 2879 2885 1:CAS:528:DyaK28XmslOntw%3D%3D 8523050
3. IC Henderson DA Berry GD Demetri, et al. 2003 Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976 983 10.1200/JCO.2003.02.063 1:CAS:528: DC%2BD2cXpsVGqs7c%3D 12637460 (Pubitemid 46594124)
4. EP Mamounas J Bryant B Lembersky, et al. 2005 Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results of NSABP B-28 J Clin Oncol 21 3686 3696 10.1200/JCO.2005.10.517 (Pubitemid 46252463)
5. M Martin A Rodriquez-Lescure A Ruiz, et al. 2008 Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer J Natl Cancer Inst 100 805 814 10.1093/jnci/djn151 1:CAS:528:DC%2BD1cXmvFWksr0%3D 18505968 (Pubitemid 351809668)
6. H Roche P Fumoleau M Spielmann, et al. 2006 Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial J Clin Oncol 24 5664 5671 10.1200/JCO.2006.07.3916 1:CAS:528:DC%2BD2sXhtVChs78%3D 17116941 (Pubitemid 46631307)
7. M Martin T Pienkowski J Mackey, et al. 2005 Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2302 2313 10.1056/NEJMoa043681 1:CAS:528:DC%2BD2MXksl2lt7c%3D 15930421 (Pubitemid 40740554)
8. P Francis J Crown A Di Leo, et al. 2008 Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial J Natl Cancer Inst 100 121 133 10.1093/jnci/djm287 1:CAS:528:DC%2BD1cXivVOnsr8%3D 18182617
9. M De Laurentis G Cancello D D'Agostino, et al. 2008 Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials J Clin Oncol 26 44 53 10.1200/JCO.2007.11.3787
10. L Norton R Simon 1986 The Norton-Simon hypothesis revisited Cancer Treat Rep 70 163 169 1:STN:280:DyaL287gsF2qsg%3D%3D 3510732
11. LJ Goldstein A O'Neill JA Sparano, et al. 2008 Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197 J Clin Oncol 26 4092 4099 10.1200/JCO.2008.16.7841 1:CAS:528:DC%2BD1cXhtFKisLfJ 18678836
12. SE Jones MA Savin FA Holmes, et al. 2006 Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer J Clin Oncol 24 5381 5387 10.1200/JCO.2006.06.5391 1:CAS:528:DC%2BD2sXisVSjtQ%3D%3D 17135639 (Pubitemid 46623169)
13. M Citron D Berry C Cirrincione, et al. 2003 Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 1431 1439 10.1200/JCO.2003.09.081 1:CAS:528:DC%2BD2cXptlCks7s%3D 12668651 (Pubitemid 46594092)
14. JA Sparano M Wang S Martino, et al. 2008 Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 1663 1671 10.1056/NEJMoa0707056 1:CAS:528:DC%2BD1cXkslCitLk%3D 18420499 (Pubitemid 351549913)
15. EH Romond EA Perez J Bryant, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F 16236738 (Pubitemid 41464706)